Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.
Oncternal Therapeutics Inc (ONCT) is a clinical-stage biopharmaceutical company advancing novel therapies for hematological malignancies and prostate cancer. This page aggregates official press releases and verified news about their innovative pipeline, including ROR1-targeted CAR T cell therapies and dual-action androgen receptor inhibitors.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. The curated collection includes announcements about trial initiations, scientific presentations, manufacturing developments, and collaborative research efforts in precision oncology.
All content is sourced directly from company filings and authorized publications, ensuring reliability for investment decision-making. Bookmark this page for streamlined access to ONCT's latest advancements in developing treatments for cancers with significant unmet needs.
Oncternal Therapeutics (Nasdaq: ONCT) announced participation of CEO James Breitmeyer in a fireside chat at H.C. Wainwright's BioConnect 2021 Conference on January 11, 2021. The discussion will highlight Oncternal's recent progress, upcoming catalysts, and strategies for 2021. The session will be available on-demand starting at 6am EST and will be accessible via a webcasting link. Oncternal focuses on developing novel oncology therapies with unmet medical needs, including investigational drugs cirmtuzumab and TK216, aimed at treating various cancers.
Oncternal Therapeutics (Nasdaq: ONCT) announced the closing of a public stock offering of 19,161,667 shares at $4.50 each, with gross proceeds of approximately $86.2 million. The underwriter exercised an option to purchase an additional 2,495,000 shares. The funds will support general corporate expenses, including clinical and preclinical development for cirmtuzumab, TK216, and the ROR1 CAR-T program. The offering was made under an existing shelf registration statement filed with the SEC.
Oncternal Therapeutics (Nasdaq: ONCT) has announced an increase in its stock offering due to high demand, purchasing 16,666,667 shares at $4.50 each, expected to close around December 14, 2020. The offering aims to generate approximately $75 million in gross proceeds before expenses. Proceeds will support the clinical development of cirmtuzumab, TK216, and ROR1 CAR-T programs. A 30-day option for underwriters to acquire an additional 2,495,000 shares has also been granted to increase volume.
Oncternal Therapeutics (Nasdaq: ONCT) has agreed to a firm underwriting agreement with H.C. Wainwright & Co. for the purchase of 8,888,889 shares at $4.50 each, expected to generate approximately $40 million before fees. The offering, set to close around December 14, 2020, includes a 30-day option for the underwriter to purchase an additional 1,333,333 shares. Proceeds will support general corporate purposes, including clinical developments for cirmtuzumab and TK216. The shares are registered under a previously filed SEC shelf registration.
Oncternal Therapeutics announced promising interim results from its Phase 1/2 CIRLL trial studying cirmtuzumab in combination with ibrutinib for relapsed/refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). The trial reported an impressive 87% objective response rate after a median follow-up of 12.1 months, with no median progression-free survival (PFS) reached yet. Notably, the combination showed good tolerability. Oncternal is in discussions with the FDA regarding pivotal study design for MCL.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced an increased offering of 7,258,065 shares of common stock at $3.10 per share, aiming to raise approximately $22.5 million before expenses. The offering, managed by H.C. Wainwright & Co., is set to close on or about November 20, 2020, pending customary conditions. An additional 1,088,709 shares may be purchased by the underwriter within 30 days. Proceeds will fund clinical development of cirmtuzumab and TK216, among other corporate purposes.
Oncternal Therapeutics (Nasdaq: ONCT) announced an underwriting agreement with H.C. Wainwright for the purchase of 6,451,613 shares of common stock at $3.10 per share. The agreement is expected to close around November 20, 2020, pending customary conditions. Gross proceeds are estimated at $20 million, which will be used for corporate purposes, including the clinical development of cirmtuzumab and TK216. Additionally, the underwriter has a 30-day option to purchase up to 967,741 additional shares. The offering is part of a previously filed shelf registration statement with the SEC.
Oncternal Therapeutics (Nasdaq: ONCT) announced promising interim results from its Phase 1 trial of TK216 for relapsed/refractory Ewing sarcoma. The interim data showed two durable complete responses (CR) among 23 patients, with a disease control rate of 43%. Patients experienced stable disease after treatment, and TK216 was generally well tolerated, with manageable side effects. TK216 has received Rare Pediatric Disease Designation from the FDA, highlighting its potential in addressing high unmet medical needs in this aggressive cancer.
Oncternal Therapeutics (Nasdaq: ONCT) will present a company overview at the Stifel Virtual Healthcare Conference on November 16, 2020, at 2:00 p.m. ET. The presentation will be led by Dr. James Breitmeyer, President and CEO. Investors can access the webcast and replay through the Events & Presentations page on the company's website. Oncternal is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies for unmet medical needs. Key candidates include cirmtuzumab and TK216, targeting critical cancer pathways.
Oncternal Therapeutics (Nasdaq: ONCT) announced FDA's Rare Pediatric Disease Designation for TK216, aimed at treating Ewing sarcoma. Interim Phase 1 data showed two complete responses among 15 evaluable patients. The company raised $10.1 million in equity financing during Q3 2020, strengthening its balance sheet. Financial results revealed a net loss of $4.4 million for Q3 2020, with $0.6 million in grant revenue and total operating expenses of $5.0 million. The current funds are expected to sustain operations into Q2 2021.
